Case Report: Sintilimab-induced erythroderma: a rare severe adverse event of a widely used PD-1 inhibitor

Erythroderma is a rare but severe cutaneous adverse reaction potentially associated with immune checkpoint inhibitors (ICIs), such as the PD-1 inhibitor sintilimab. Herein, we report a case of a patient with advanced gastric cancer who developed progressive generalized erythroderma (involving >90% of the body surface area, CTCAE grade 3) during sintilimab-based chemotherapy. The eruption persisted despite the discontinuation of other suspected drugs. Laboratory findings revealed marked eosinophilia and elevated IL-5 and IL-10 levels, suggesting a Th2-dominant immune response. Systemic corticosteroids provided limited improvement, while a single dose of dupilumab was followed by substantial relief of pruritus and partial resolution of erythema. However, the independent contribution of dupilumab cannot be definitively established due to concurrent therapies. This case highlights the diagnostic challenge of identifying the offending agent in combination regimens. Dupilumab may represent a potential adjunctive therapeutic option for corticosteroid-refractory ICI-induced erythroderma, warranting further investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fmed.2026.1925289
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Sintilimab-induced erythroderma: a rare severe adverse event of a widely used PD-1 inhibitor

Jueying Wang, Qi Lyu, Jingjing Ding, Wanyue She et al.
3 links
Frontiers in Medicine
Cancer Immunotherapy and Biomarkers
article

Case Report: Sintilimab-induced erythroderma: a rare severe adverse event of a widely used PD-1 inhibitor

Jueying Wang, Qi Lyu, Jingjing Ding, Wanyue She, Maidina Aimurula, Xinyi Zhang, Yu Gu, Meng Zhou
article en

Abstract

Erythroderma is a rare but severe cutaneous adverse reaction potentially associated with immune checkpoint inhibitors (ICIs), such as the PD-1 inhibitor sintilimab. Herein, we report a case of a patient with advanced gastric cancer who developed progressive generalized erythroderma (involving >90% of the body surface area, CTCAE grade 3) during sintilimab-based chemotherapy. The eruption persisted despite the discontinuation of other suspected drugs. Laboratory findings revealed marked eosinophilia and elevated IL-5 and IL-10 levels, suggesting a Th2-dominant immune response. Systemic corticosteroids provided limited improvement, while a single dose of dupilumab was followed by substantial relief of pruritus and partial resolution of erythema. However, the independent contribution of dupilumab cannot be definitively established due to concurrent therapies. This case highlights the diagnostic challenge of identifying the offending agent in combination regimens. Dupilumab may represent a potential adjunctive therapeutic option for corticosteroid-refractory ICI-induced erythroderma, warranting further investigation.

Frontiers in MedicineVol. 13
Nanjing University of Chinese Medicine (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon